Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236546 · ClinicalTrials.gov registry record · NA
FDG-PET in Advanced Melanoma
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT02236546 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 3 participants.
The verdict
NCT02236546, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, \[18F\]fluorodeoxyglucose (FDG), which selectively accumulates in tumors. FDG-PET/CT of advanced melanoma before, during, and after treatment may improve methods for predicting which patients may benefit from therapy.
Interventions
- DEVICE computed tomography
- DEVICE positron emission tomography
- DIAGNOSTIC_TEST [18F]fluorodeoxyglucose
- OTHER Molecular assays on biopsied tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02236546
The ClinicalTrials.gov registry entry for NCT02236546 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which computed tomography is the first listed.
NCT02236546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02236546 about?
NCT02236546 is a clinical study titled "FDG-PET in Advanced Melanoma". This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, \[18F\]fluorodeoxyglucose (FDG), which selectively accumula...
What is the current status of trial NCT02236546?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2012-05. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02236546?
The interventions under investigation include: computed tomography (DEVICE), positron emission tomography (DEVICE), [18F]fluorodeoxyglucose (DIAGNOSTIC_TEST), Molecular assays on biopsied tissue (OTHER).
Who is sponsoring clinical trial NCT02236546?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.